that phosphorylation of RalA S194 by Aurora A kinase is critical for PDAC tumorigenesis. We sought to evaluate the Aurora A kinase-selective inhibitor MLN8237 as a potential indirect anti-RalA targeted therapy for PDAC. We utilized a site-specific phospho-S194 RalA antibody and determined that RalA S194 phosphorylation levels were elevated in a subset of PDAC cell lines and human tumors relative to unmatched normal controls. Effects of MLN8237 on anchorage-independent growth in PDAC cell lines and growth of patient-derived xenografts (PDX) were variable, with a subset of cell lines and PDX showing sensitivity. Surprisingly, RalA S194 phosphorylation levels in PDAC cell lines or PDX tumors did not correlate with MLN8237 responsiveness. However, we identified Ki67 as a possible early predictive biomarker for response to MLN8237 in PDAC. These results indicate that MLN8237 treatment may be effective for a subset of PDAC patients independent of RalA S194 phosphorylation. Ki67 may be an effective pharmacodynamic biomarker to identify response early in the course of treatment.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death in the United States accounting for approximately 37,000 deaths annually with a five year survival rate of less than five percent (1) . Gemcitabine remains the most effective treatment for patients with locally advanced and metastatic PDAC, with only a 24% response rate and median survival of only 5.6 months.
Therefore, there remains a crucial need for the development and evaluation of new targeted therapies (2, 3) .
The frequent mutational activation of KRAS in PDAC and critical importance of K-Ras-driven signaling in PDAC progression has led to increased efforts to identify K-Ras-targeted therapies. There is increasing evidence for the importance of the RalA and RalB small GTPases in mutant Ras-driven oncogenesis (4, 5) . RNAi knockdown of endogenous RalA in PDAC cells significantly impaired anchorage-independent growth whereas knockdown of RalB impaired Matrigel invasion in vitro and experimental metastasis in vivo (6) .
Importantly, RalA-GTP and RalB-GTP levels were significantly higher in PDAC cell lines and in patient tumors relative to normal matched and unmatched samples (6, 7) . Taken together, these studies suggest that therapeutic inhibition of Ral may be an effective therapy for KRAS mutant PDAC.
Like Ras, Ral is a GTPase and therefore not a tractable target for direct inhibition. However, we and others have determined that Ral growth regulatory activities are regulated by phosphorylation. Hahn and colleagues showed that serine-threonine protein phosphatase 2A dephosphorylation of RalA at S183 and 5 S194 abolished RalA transforming activity (8) . Two other studies determined that S194 could be phosphorylated by Aurora A and that this phosphorylation was essential for RalA transforming activity (9) and RalA-dependent PDAC anchorage-independent and tumorigenic growth (10) . Aurora A phosphorylation alters RalA subcellular localization and interaction with effectors (10, 11) .
Activation of Aurora A promotes mitochondrial localization of RalA and promotes mitochondrial fission (11) , which may present a mechanism for Aurora A contribution to tumorigenesis (12). These findings suggest that protein kinase inhibitors may be an effective approach for inhibition of Ral.
Aurora A kinase (AAK) is a member of a family of serine-threonine kinases that regulate mitosis. A number of proteins associated with mitosis are phosphorylated by AAK through spatially and temporally controlled mechanisms (13) . Amplification of the AURKA gene is commonly found in a number of malignancies (14) (15) (16) and overexpression of AAK is associated with high tumor grade and poor prognosis (15, (17) (18) (19) (20) . Surprisingly, it does not independently possess transforming activity in rodent cells or mouse models of PDAC (21, 22) , suggesting the necessity to cooperate with other oncogenic pathways to promote tumorigenesis.
This evidence suggests that targeting RalA phosphorylation with AAK inhibitors may be a viable therapeutic option for the treatment of pancreatic cancer. MLN8237 is a novel and selective AAK inhibitor that has entered Phase III clinical trials. We investigated the effectiveness of MLN8237 at inhibiting anchorage-independent growth of PDAC cell lines and patient-derived xenograft 6 (PDX) growth in vivo. PDX models maintain heterogeneity and allow tumor cell growth in the context of a microenvironment (23) . This is especially relevant in PDAC due to the contribution of desmoplasia to the pathology and treatment of the disease (24, 25) . The method is previously described (26) (27) (28) (29) and involves implantation of small tumor fragments taken from the patient and directly implanted into immunodeficient mice. Tumors are subsequently propagated and expanded into several animals and subjected to treatment with anticancer therapies.
In the current study, we found that S194 RalA phosphorylation was increased in a subset of PDAC cell lines and human tumors and correlated with autophosphorylation of Aurora A (indicative of activation). This suggested that targeting RalA phosphorylation with AAK inhibitors may prove to be a viable therapeutic option for the treatment of pancreatic cancer. Therefore the goal of the current study was to investigate whether an AAK selective inhibitor, MLN8237, may be used as a therapeutic strategy to target RalA in PDAC. Cell lines were passaged for fewer than six months upon acquisition from ATCC.
MATERIALS AND METHODS

Human
ATCC authentication was performed using short tandem repeat DNA profiling.
HuPT3 cells were obtained from Dan Billadeau (Mayo Clinic, Rochester, MN).
No authentication was performed on the HuPT3 cell line by the authors. The 7 immortalized human pancreatic duct-derived (HPNE) cells were described previously (30, 31) .
Western blot analysis. Whole cell lysates were isolated in NP40 lysis buffer.
Human tumor lysates from flash frozen samples were homogenized in NP40 lysis buffer, resolved by SDS-PAGE, and evaluated by western blot analyses with the primary antibodies: rabbit anti-phospho-RalA (S194) (Millipore), mouse anti-RalA (BD Bioscience), rabbit anti-phospho-Aurora A (T288) (Cell Signaling Technology), rabbit anti-Aurora A (Millipore), mouse anti-vinculin (Sigma), mouse anti-β-tubulin (Sigma), mouse anti-HA (Covance) and species appropriate HRPconjugated secondary antibodies (Pierce). Membranes were subjected to detection using ECL. Densitometry measurements were performed using ImageJ software.
Purification of recombinant GST-RalA and in vitro phosphorylation with
PKA.
RalA cDNA was subcloned into pGEX-2T in frame with sequences encoding an N-terminal glutathione S-transferase (GST) tag using the BamHI site. pGEX-2T RalA, and empty vector were transformed into Rosetta 2 bacterial expression cells. Protein expression was induced with 1 mM IPTG. Bacterial pellets were resuspended in Triton-X-100 based lysis buffer and sonicated.
GST-bound proteins were isolated with glutathione-sepharose beads. 
RESULTS
Effects on anchorage-dependent and -independent growth of PDAC cell lines are variable in response to MLN8237
We investigated whether MLN8237 was effective at inhibiting anchoragedependent and -independent growth of PDAC cell lines. AAK activity was assessed by the level of auto-phosphorylation at threonine 288 (pT288 Aurora A), required for AAK activity, in PDAC cell lines synchronized with a thymidine/nocodazole block (Fig. 1A) . We evaluated the effects of MLN8237 on anchorage-dependent and -independent growth in a panel of ten PDAC cell lines with variable T288 Aurora A phosphorylation levels. Although the cell lines exhibited a range of sensitivity in anchorage-dependent MTT assays, IC50
values from 293nM to greater than 10,000 nM, MLN8237 effects on anchorageindependent growth were much more potent. Brdu assays were also used to assess the effects of MLN8237 on anchorage-dependent growth in Capan-2 and MIA PaCa-2 cell lines. The IC50 values were 1372.8nM and 147.8nM in Capan-2 and MIA PaCa-2 cell lines, respectively. The cell lines exhibited variable sensitivity to MLN8237 in soft agar with IC50 values ranging from 3.3 to 236.8nM (Table 1 and Fig. 1B, C) . Following treatment with MLN8237 we observed a concentration-dependent decrease in Aurora A T288 phosphorylation (Fig. 1D ), validating that MLN8237 was effective at inhibiting AAK activity.
MLN8237 inhibits tumor growth in a subset of PDAC PDX tumors
Because the PDX model has emerged as a better predictive model for evaluation of novel therapeutics (23, 27) , we assessed the ability of MLN8237 to inhibit We next sought to identify a kinase-activity specific biomarker for predicting MLN8237 responsiveness in PDAC cell lines and PDX tumors. We investigated whether RalA S194 phosphorylation was a biomarker for responsiveness. In order to determine the in vivo and clinical incidence of RalA S194 phosphorylation, we examined the phosphorylation levels using a rabbit polyclonal antibody made against a RalA peptide sequence that contained phosphorylated S194. We determined that this antibody was specific for RalA phosphorylated at S194 using lysates from PANC-1 cells expressing RalAspecific shRNA to suppress endogenous RalA expression and with ectopic expression of wild type or S194A RalA from RNAi-insensitive cDNA expression vectors (Fig. 3A) . In order to further validate the antibody, we phosphorylated GST-RalA in vitro using the purified catalytic subunit of PKA (previously shown to phosphorylate RalA in vitro (36) ) and found that the antibody specifically recognized purified GST-RalA in the presence of PKA and ATP ( Supplementary   Fig. 2 ).
RalA S194 phosphorylation levels were examined in patient samples and high levels were observed in a subset of the tumors compared to unmatched normal controls (Fig. 3C) . Lysates from a panel of PDAC cell lines were examined for S194 phosphorylation levels and a subset of PDAC cell lines showed high levels of phosphorylation compared to non-transformed human nestin-positive pancreatic epithelial cells (HPNE) (Fig. 3B) . Interestingly, all cell lines with high levels of pS194 RalA (BxPC3, MIAPaCa-2, Capan-2, Panc 10-05, SW1990, and HuPT3) also had high levels of pT288 Aurora A (Fig. 1A and Fig.   3B ). However, there was not a direct correlation between MLN8237 sensitivity and the level of basal RalA S194 phosphorylation. The correlation coefficient between pS194 RalA levels and soft agar IC50 values was -0.41 but this was not significantly different from zero (p-value 0.23). We observed no significant reduction in S194 RalA phosphorylation following MLN8237 treatment.
Furthermore, the trends in the changes in pS194 RalA phosphorylations levels following treatment did not vary with MLN8237 sensitivity.
Finally, vehicle treated PDX tumors were examined to determine whether basal RalA S194 phosphorylation levels were predictive of responsiveness. We found no correlation between RalA S194 phosphorylation levels and tumor response to MLN8237, suggesting that RalA phosphorylation was not a predictive biomarker (Fig. 3D-E) . RalA phosphorylation levels were also 
examined following treatment with MLN8237 to determine whether changes in phosphorylation occurred with treatment. We observed no consistent changes in RalA S194 phosphorylation following MLN8237 treatment ( Supplementary Fig. 3) in responders (PancT4) versus non-responders (PancT6). RalA phosphorylation was also examined in tumors from mice subjected to short-term (4, 8, and 24 h) MLN8237 treatments and no consistent changes were noted (data not shown).
MLN8237 treatment does not alter intracellular RalA localization in PDAC cell lines
RalA S194 phosphorylation by AAK can alter subcellular localization (10).
We investigated whether MLN8237 treatment altered the intracellular localization (Fig. 4A-D) .
Expression of a RalA S194 phosphomimetic mutant in PDAC cells enhances anchorage-independent growth but does not diminish MLN8237 responsiveness To further investigate RalA phosphorylation as a target of MLN8237 we expressed a S194 phosphomimetic mutant (S194D) as a putative Aurora Aindependent variant in CFPAC-1 and MIA PaCa-2 cells (Fig. 5A ) and evaluated anchorage-independent growth. As shown in Fig. 5B , ectopic expression of the S194D RalA mutant enhanced anchorage-independent growth two to three-fold when compared to empty vector controls. However, expression of this Aurora A- independent RalA variant did not reduce the sensitivity of PDAC cells to treatment with MLN8237 (Table 3 and Fig. 5B ), suggesting that RalA may not be a dominant target of MLN8237 through inhibition of Aurora A. In addition, cells expressing S194D RalA exhibited decreases in Aurora A T288 phosphorylation similar to those seen in vector control cells (Fig. 5C) .
Ki67 is a possible early biomarker for pancreatic PDX response to MLN8237
We sought to identify a biomarker that would indicate responsiveness in tumors treated with MLN8237. Increases in mitotic index, as quantitated by the phosphorylation levels of S10 in histone H3, were shown to be an early pharmacodynamic biomarker of response for Aurora A inhibition to the AAK inhibitor MLN8054 (37) . Therefore, we investigated whether mitotic index could serve as a biomarker for MLN8237 responsiveness in our model. We examined the percentage of phosphorylated S10 histone H3-positive cells in responsive and non-responsive tumors treated with either vehicle or 30 mg/kg MLN8237 and harvested after 4 h, 8 h, 12 h, and 24 h. There was no significant increase in mitotic index in responsive or non-responsive tumors (Supplementary Fig. 4A ).
This was also true in the tumors treated for 28 days with vehicle or 30 mg/kg MLN8237 ( Supplementary Fig. 4B ), suggesting that mitotic index was not a biomarker for responsiveness in our PDX model. (Fig. 6A, B) . Although each individual harvest time point was not statistically significant due to limited sample size, the reduction in Ki67-positive nuclei at all time points combined was significant. There was no change in Ki67-positive nuclei following MLN8237 treatment in the PancT6 tumors at any of the time points (Fig. 6A, B) . A similar trend was observed in the tumors treated for 28 days with MLN8237 (Fig. 6C ). As seen with the single treatment time points, there was no change in the percentage of Ki67-positive nuclei in the PancT6 tumors following 28 days of MLN8237 treatment (Fig. 6C) . These data suggest that Ki67 may be an early pharmacodynamic biomarker to identify tumor responsiveness after treatment with MLN8237.
DISCUSSION
The high prevalence of activating KRAS mutations in PDAC tumors and apparent KRAS oncogene addiction in pancreatic tumors (39) (40) attractive druggable target downstream of oncogenic Ras activation. The previous studies identifying RalA S194 phosphorylation relied primarily on ectopic expression of phosphorylation-deficient and phosphomimetic mutants and endogenous RalA-depleted PDAC cells. We therefore sought to evaluate endogenous RalA S194 phosphorylation levels in PDAC cell lines and human tumors using a S194 phospho-specific antibody. Our finding that RalA S194 phosphorylation levels were elevated in a subset of cell lines and tumors prompted us to hypothesize that anti-RalA targeted therapies may benefit those patients exhibiting elevated phosphorylation.
The recent characterization of RalA S194 as a substrate for AAK (9, 10) and our finding that RalA S194 phosphorylation levels correlated with Aurora A activation, as indicated by T288 phosphorylation, prompted us to investigate whether MLN8237 could be an effective anti-RalA therapy for pancreatic cancer.
Most cell lines were largely insensitive to MLN8237 using the MTT assay to assess anchorage-dependent growth. However, studies from our laboratory and previous studies (41) have demonstrated much lower IC50 values using the BrdU assay, which suggests that the MTT assay is not a sensitive assay for MLN8237 activity. We found that a subset of cell lines showed inhibition of anchorageindependent growth after treatment of MLN8237 at nanomolar concentrations.
However, we were unable to correlate this with RalA S194 phosphorylation levels. AAK activity is temporally controlled with peak activity during mitosis (42) .
It is possible that Aurora A phosphorylation of RalA at S194 is strictly temporally controlled, making it difficult to observe consistent changes following MLN8237 treatment in an asynchronous cell population. However, our data demonstrating that overexpression of a phosphomimetic (S194D) RalA mutant does not reduce sensitivity to MLN8237 inhibition of anchorage-independent growth argues that perhaps RalA phosphorylation is not a critical target for MLN8237 anti-tumor activity. We also found that RalA localization was unaffected by treatment with MLN8237 in multiple PDAC cell lines. This is in contrast to earlier studies using predominantly overexpression studies to assess a role for AAK in RalA localization. Although, Counter and colleagues (10) 
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Aurora A-specific inhibitor MK-8745 in non-Hodgkin lymphoma cells (43). Except for this example, very few predictive biomarkers have been characterized for AAK inhibitor responsiveness. Therefore, it is of great interest that Ki67 does appear to be an early biomarker of response in PDAC PDX. More studies will be needed to determine if baseline Ki67 is a predictive biomarker of response to MLN8237.
In conclusion, we have determined that Aurora A activity as determined by auto-phosphorylation and RalA S194 phosphorylation levels are elevated in a subset of PDAC cell lines and tumors. Elevated Aurora A activity correlated with high RalA S194 phosphorylation levels. We observed variable responsiveness of PDAC cell lines and PDX to MLN8237. Basal RalA S194 phosphorylation levels or changes in RalA S194 following MLN8237 treatment were not predictive of responsiveness, indicating that other protein kinases or phosphatases may regulate S194 phosphorylation in PDAC cells. These data suggest that further investigation of MLN8237 in a subset of PDAC patients is warranted, though our preclinical data suggests that activity will be RalA-independent and that RalA S194 phosphorylation will not be a predictive biomarker of response. However, we have identified decreases in Ki67-positive cells as a potential early pharmacodynamic biomarker of response to MLN8237 in PDAC. Ki67 would be attractive as it is already widely used in clinical practice and does not suffer from the challenges of phosphospecific antibodies. Further investigation is warranted to determine the clinical feasibility of utilizing Ki67 as a pharmacodynamic biomarker. Finally, it appears that AAK-mediated phosphorylation of RalA S194 
